Please login to the form below

Not currently logged in

Efficacy trials get underway for HIV vaccine in South Africa

Study hopes to provide partial immunity against the virus

Amazing Africa 

Researchers are testing an HIV vaccine in efficacy trials for the first time in seven years in the hope that the candidate will provide at least partial immunity against the virus.

The study - called HVTN 702 - is being conducted in South Africa and will test an updated version of an experimental vaccine developed by researchers at the US National Institute of Allergy and Infectious Diseases (NIAID) that was shown to have around 32% efficacy in an earlier trial (RV144).

The vaccine regimen is based on a canarypox vector-based vaccine called ALVAC-HIV from Sanofi Pasteur and a two-component gp120 protein subunit vaccine supplied by GlaxoSmithKline (GSK), and should yield results in 2020.

The new regimen has been altered to try to increase the magnitude and duration of immune responses to the vaccine, for example by targeting a subtype of HIV predominant in South Africa, increasing the number of shots and incorporating an immune-stimulating adjuvant (MF59) also supplied by GSK.

Around 5,400 men and women will be enrolled in HVTN 702 and will receive an initial vaccination with the regimen followed by a booster shot a year later. The safety of the vaccine was shown in a smaller study (HVTN 100).

NIAID director Anthony Fauci said that even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection such as South Africa, which sees more than 1,000 people newly infected with the virus every day.

"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," he predicted.

The HIV Vaccine Trials Network - part of the P5 public-private partnership behind the vaccine's development along with the organiser of the trial - has said that it believes that if the vaccine can show a 50% protective efficacy rate at two years it could be enough to support regulatory approvals.

In addition to the NIAID, the two pharma companies and the HVTN, the P5 brings together the Bill & Melinda Gates Foundation (BMGF), the South African Medical Research Council and the US Military HIV Research Programme.

HVTN 702 is being funded to the tune of $130m, with the bulk of that money coming from the NIAID and BMGF.

Article by
Phil Taylor

29th November 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...